Skip to main content
OpenTrials
Completed

NCT Number: NCT04473417

Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects

This is the phase I study to evaluate the pharmacokinetics and safety of DA-2811 and Forxiga® after a single oral dose in healthy volunteers.

The study will also compare the pharmacokinetics and safety profiles of DA-2811 under fasting and fed states in healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

19 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Bundangseoul national unversity hospital

Sŏngnam, GyeonggiDo, South Korea

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male and/or female subjects
  • BMI between 18.5 and 29.9 kg/m2 and weigh at least 50 kg
  • Volunteer who totally understands the progress of this clinical trial, make decision by his or her free will, and signed a consent form to follow the progress.

Exclusion criteria

  • Volunteer who has present or past history of clinically significant cardiovascular, respiratory, urinary, gastrointestinal, hepatic, renal, skin, immunological, musculoskeletal, endocrinal, neurological, psychiatric and/or hematological disease
  • Vulnerable to dehydration due to poor oral intake or clinically significant dehydration as judged by the investigator
  • History of gastrointestinal disease or any gastrointestinal surgery(except for simple appendectomy, hernia surgery, hemorrhoid surgery)
  • History of diseases that may impact absorption, distribution, metabolism, and excretion of the study drugs.
  • Hypersensitivity to a drug containing an ingredient of the investigational product, Sodium glucose transporter-2 inhibitors, additional ingredient or other drugs (e.g., aspirin, antibiotics, etc.) or medical history of clinically significant hypersensitivity.
  • History of clinically significant active chronic disease
  • volunteer who has genetic disorder like lapp lactase deficiency or glucose-galactose malabsorption.
  • History of clinically significant allergies including drug allergies
  • History of drug abuse or addicted
  • Clinical laboratory test values are outside the accepted normal range
  • Participation in another clinical trial within 6 months of the first IP administration
  • Sexually active women of childbearing potential not consistently and correctly practicing birth control by dual contraceptive method until 2 months after last IP administration
  • Breast-feeding period, pregnant, or positive to urine pregnancy test (conducted before the first drug administration)
  • Subjects considered as unsuitable based on medical judgement by investigators

Treatment and study plan

Forxiga

Drug

single dose administration after 10hr fasting

DA-2811

Drug

single dose administration after 10hr fasting

Primary outcomes

  1. AUClast

    Time frame: pre-dose~48 hours post-dose

    Area under the plasma concentration-time curve from time zero to time the last quantifiable time

  2. Cmax

    Time frame: pre-dose~48 hours post-dose

    Maximum plasma concentration

Secondary outcomes

  1. AUC(0 - ∞)

    Time frame: pre-dose~48 hours post-dose

    Area under the plasma concentration versus time curve from time zero to extrapolated infinite time (0 - ∞)

  2. Tmax

    Time frame: pre-dose~48 hours post-dose

    Time to reach maximum plasma concentration following drug administration

  3. t1/2

    Time frame: pre-dose~48 hours post dose

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Sponsors and collaborators

Lead sponsor

Dong-A ST Co., Ltd.

Industry

Registry information

Official study title

An Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA-2811 in Healthy Subjects

Acronym: DA-2811

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Jul 16, 2020
Registry last updated
Mar 5, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.